MedTrace Logo

Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine

NCT05857566 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-11-18

No results posted yet for this study

Summary

This Phase 1b Study RDX-002-22-09 has been planned to evaluate the effect of RDX-002 on postprandial triglycerides and ApoB48 levels in normal healthy subjects treated with the atypical antipsychotic drug, olanzapine.

Conditions

  • Drug-induced Weight Gain

Interventions

DRUG

RDX-002

A potent, selective, and gut-specific microsomal triglyceride transfer protein (MTP) inhibitor.

Sponsors & Collaborators

  • Response Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Tricia Stamp, PhD, PA-C · Nucleus Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-16
Primary Completion
2023-07-13
Completion
2023-09-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05857566 on ClinicalTrials.gov